Please login to the form below

Not currently logged in
Email:
Password:

Samsung BioLogics

This page shows the latest Samsung BioLogics news and features for those working in and with pharma, biotech and healthcare.

Biogen launches Remicade biosimilar in the UK

Biogen launches Remicade biosimilar in the UK

Developed by Samsung Bioepis - a joint venture between Biogen and Samsung BioLogics - and marketed in the EU by Biogen, Flixabi (infliximab) won EU marketing authorisation in May this year.

Latest news

  • Second Remicade biosimilar given green light in Europe Second Remicade biosimilar given green light in Europe

    Second Remicade biosimilar given green light in Europe. Samsung Bioepis’ Flixabi provides another lower-cost treatment option. ... year. It has been developed by Samsung Bioepis - a joint venture between Samsung BioLogics and Biogen - and will be sold

  • UCB to sell Biogen Idec’s MS drugs in Asia UCB to sell Biogen Idec’s MS drugs in Asia

    US-based Biogen Idec's previosu experience in the Asian market includes a biosimialrs joint venture with Korea's Samsung Biologics known as Samsung Bioepis.

  • Biogen Idec licenses anti-TNF biosimilars Biogen Idec licenses anti-TNF biosimilars

    Biogen Idec licenses anti-TNF biosimilars. Treatment prospects emerge from joint venture with Samsung Biologics. ... Biogen Idec says it has licensed multiple biosimilars of anti-tumour necrosis factor (TNF) developed at its joint venture with Korea's

  • Roche signs biologics partnership with Samsung Roche signs biologics partnership with Samsung

    Samsung BioLogic manufacturing plant. Swiss pharma company Roche has signed a biologics manufacturing deal with Samsung BioLogics. ... Tae-Han Kim, president and CEO of Samsung BioLogics, said: "We are pleased to announce this strategic manufacturing

  • BMS signs 10-year biologic manufacturing deal with Samsung BMS signs 10-year biologic manufacturing deal with Samsung

    Bristol-Myers Squibb (BMS) has signed a long-term agreement with Samsung BioLogics that will see the Korean firm manufacture one of its antibody cancer drugs. ... Tae-Han Kim, president and CEO of Samsung BioLogics, said: "We are pleased to announce this

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    Two weeks prior to the announcement of the collaboration between Amgen and Watson, Biogen Idec and Samsung Biologics announced the establishment of a $300m joint venture to develop and commercialise biosimilars.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics